Kymera IPO Presentation Deck

Target Date H1 2020 H2 2020/H1 2021 • HS: n=30 AD: n=10 NI Study Single-site non-interventional study • Whole blood, plasma and skin biopsies collected at single time point Milestones Study Start Data readouts from skin and blood KYMERA • Biomarker endpoints in blood and skin: IRAK4, cytokines, acute phase reactants IND KT-474 Development Plan Phase 1 NHV SAD/MAD Target Date Milestones H1 2021 IND Filing and Study Start H2 2021 NHV SAD/MAD data H2 2021 Patient cohort in MAD • Randomized, pbo-controlled, dose escalation study • SAD and MAD (14 daily doses) • Up to 100 adult healthy volunteers Primary endpoint: Safety • Secondary endpoints: PK and PD (POB) • IRAK4 levels in blood and skin • Levels of pro-inflammatory cytokines • Ex-vivo stimulation of PBMC • Plasma levels of hsCRP • Small patient cohort of top MAD dose to confirm PKPD POB Phase 2 Target Date Milestones 2022 Clinical POC • Randomized, pbo-controlled, study in pts in indications such as HS, AD, RA POC

View entire presentation